19. The crystalline Sovaprevir form of Claim 17, wherein polymorph E is characterized by an X-ray powder diffraction pattern obtained from a Cu Kα source which comprises peaks at 2θ values of

4.5, 10.9, 17.4, 20.2, and 21.7 +/- 0.2; or

9.0, 12.3, 18.6, 20.7, and 22.2 +/- 0.2; or

9.7, 13.7, 19.4, and 21.3 +/- 0.2.

20. The crystalline Sovaprevir form of Claim 17, wherein polymorph E has a primary endotherm at 156°C as determined by DSC.

21. A composition comprising a crystalline form of Sovaprevir wherein at least 90 wt% of the Sovaprevir is

the Form A polymorph, the Form B polymorph, the Form C polymorph, the Form E polymorph, or a combination thereof.

22. The composition of Claim 21, wherein the composition comprises less than about 10 wt% of a Form D polymorph.

23. The composition according to Claim 21, wherein essentially all of the Sovaprevir is the Form A polymorph.

24. A pharmaceutical composition comprising Sovaprevir according to Claim 21, in combination with a physiologically acceptable carrier or excipient.

25. A pharmaceutical composition according to Claim 24 wherein the composition is a tablet or a capsule.

26. A method for treating a disorder, comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to Claim 25.

27. A method according to Claim 26, wherein the patient is a human.

28. A method Claim 26, wherein the pharmaceutical composition is administered orally.

19. The crystalline Sovaprevir form of Claim 17, wherein polymorph E is characterized by an X-ray powder diffraction pattern obtained from a Cu Ka source which

comprises peaks at 20 values of

4.5, 10.9, 17.4, 20.2, and 21.7 +/- 0.2; or

9.0, 12.3, 18.6, 20.7, and 22.2 +/- 0.2; or

9.7, 13.7, 19.4, and 21.3 +/- 0.2.

20. The crystalline Sovaprevir form of Claim 17, wherein polymorph E has a primary endotherm at 156°C as determined by DSC.

21. A composition comprising a crystalline form of Sovaprevir wherein at least 90 wt% of the Sovaprevir is

the Form A polymorph, the Form B polymorph, the Form C polymorph, the Form E polymorph, or a combination thereof.

22. The composition of Claim 21, wherein the composition comprises less than about 10 wt% of a Form D polymorph.

23. The composition according to Claim 21, wherein essentially all of the Sovaprevir is the Form A polymorph.

24. A pharmaceutical composition comprising Sovaprevir according to Claim 21, in combination with a physiologically acceptable carrier or excipient.

25. A pharmaceutical composition according to Claim 24 wherein the composition is a tablet or a capsule.

26. The use of the pharmaceutical composition according to Claim 25 in the manufacture of a medicament for the treatment of a disorder.

27. The medicament according to Claim 26 for treating a human patient.

28. The medicament according to Claim 26, wherein the medicament is administered orally.